Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
905.3 USD | +1.24% | -3.21% | +3.17% |
03:58pm | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
03:20pm | The market is pinning its hopes on earnings reports |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.17% | 96.09B | |
-3.29% | 102B | |
-1.02% | 22.05B | |
-18.11% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.29% | 14.01B | |
+1.71% | 13.38B | |
+22.48% | 11.01B | |
-18.58% | 9.12B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Secures European Commission Approval for Antibody Cocktail to Treat, Prevent COVID-19